Silence Therapeutics reported positive topline results from its Phase 2 SANRECO trial for divesiran in polycythemia vera, meeting primary and secondary endpoints with strong efficacy and safety signals [S2][S8]. The company maintains a robust cash position of approximately $72 million as of June 2026, supporting ongoing R&D investments amid continued net losses [F1][S2]. Positioned within the RNA interference (RNAi) therapeutics field, Silence is progressing toward Phase 3 trials with regulatory milestones expected, reflecting a typical biotech development cycle. Governance over cybersecurity risks complements operational stability during its strategic transition to U.S. issuer status [S1][S2].